U.S. Markets closed

Wired News – Kitov Pharma Signs Consensi(TM) Commercialization Deal with Changshan Pharma in China

Stock Monitor: Array BioPharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Kitov Pharma Ltd (NASDAQ: KTOV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KTOV as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it has inked a definitive license and commercialization deal with China-based Hebei Changshan Biochemical Pharmaceutical Co., Ltd ("Changshan"), granting the latter exclusive rights to import, manufacture, and distribute the Company's lead drug candidate, Consensi™, in China. Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for Array BioPharma Inc. (NASDAQ: ARRY), which also belongs to the Healthcare sector as the Company Kitov Pharma. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Kitov Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


Deal Details

  • Upon receipt of marketing authorization in China, Changshan will have the exclusive rights and license to import, manufacture, distribute, and sell Consensi™ in China, Taiwan, Hong Kong, and Macao.
  • Changshan will be responsible for financing and seeking regulatory approval for Consensi™ in China.
  • As per the agreement terms, Kitov is entitled to receive up to an aggregate of $3.5 million for the US Food and Drug Administration (FDA) approval of Consensi™, which has a PDUFA date of May 31, 2018, and for China regulatory milestones.
  • Kitov will also receive an aggregate of $6.0 million for pre-defined commercial milestones, and up to 12% royalties on net sales.

Changshan has a Strong Track Record of Successfully Launching Pharmaceutical Products in China

Dr. Gil Ben-Menachem, Vice President, Business Development of Kitov, stated that the Company looks forward to building a long-term relationship with Changshan in China. Changshan has a strong track record of successfully launching and marketing pharmaceutical products in China. Dr. Ben-Menachem added that this was the second commercialization agreement for Consensi™ in Asia, further confirming its global sales potential. Kitov continues to work diligently towards finalizing additional commercialization agreements in the US and in other territories.

News reports suggest that post announcement of the news, Kitov's shares surged in pre-market trade.

Kitov's License Agreement for Consensi™ in South Korea

In March 2017, Kitov signed a definitive license agreement for Consensi™ for the territory of South Korea with Kuhnil Pharmaceutical Co. Ltd ("Kuhnil"), which is a leading South Korea-based pharmaceutical organization. Following the agreement, Kuhnil got the exclusive rights and license to manufacture, distribute, and sell Consensi™ in South Korea. The commercial launch of the product in South Korea is estimated to take place in 2019.

About Consensi™

Consensi™, formerly known as KIT-302, is a combination drug intended to simultaneously treat pain caused by osteoarthritis, and hypertension, which is a common side effect of stand-alone drugs that treat osteoarthritis pain. Consensi™ is comprised of two FDA-approved drugs, celecoxib (Celebrex®), a non-steroidal anti-inflammatory COX-2 inhibitor (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate (Norvasc®), a calcium channel blocker for lowering blood pressure. According to the IMS, the total annual NSAID market in China is estimated of hundreds of millions of dollars.

About Hebei Changshan Biochemical Pharmaceutical Co., Ltd

Changshan is a fully-integrated, publicly-traded pharmaceutical organization with headquarters in Shijiazhuang, Hebei, China. It is a leading supplier of Heparin and Low Molecular Weight Heparin pharmaceutical products from its state-of-the-art manufacturing facilities. Changshan has a long history of international collaborations leading to a deep and diverse pipeline of innovative products across various therapeutic categories and dosage forms.

About Kitov Pharma Ltd

Founded in 2010 and headquartered in Israel, Kitov is an innovative biopharmaceutical drug development Company. Leveraging deep regulatory and clinical-trial expertise, Kitov's veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development and approval.

Stock Performance Snapshot

May 14, 2018 - At Monday's closing bell, Kitov Pharma's stock surged 10.00%, ending the trading session at $2.64.

Volume traded for the day: 1.91 million shares, which was above the 3-month average volume of 112.77 thousand shares.

Stock performance in the last month – up 14.78%; previous three-month period – up 10.00%; past twelve-month period – up 46.67%; and year-to-date - up 15.79%

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.7% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors